Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Quarterly Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) released its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07), Zacks reports. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 26.77% and a negative net margin of 34.40%.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Apotex transaction closed July 1, delivering $100 million in cash at closing, with an additional $11 million expected from inventory and transition payments and a potential $10 million milestone payment.
• Cumberland declared a $1.50-per-share special dividend totaling approximately $22 million while retaining enough capital to fund operations for more than five years and maintain over $50 million in reserves.
• The company is pivoting fully toward its ifetroban pipeline, with anticipated 2026 milestones including systemic sclerosis top-line results, interim efficacy data from the idiopathic pulmonary fibrosis study, and further regulatory guidance for Duchenne muscular dystrophy.
• Management cited encouraging clinical progress: ifetroban’s DMD study produced supportive biomarker findings, the systemic sclerosis trial completed enrollment, and a Vanderbilt oncology study reported fewer metastatic recurrences and metastasis-related deaths in the treatment arm.
• Following the divestiture, Cumberland will no longer receive revenue from its commercial brands and will operate primarily as a development-stage biopharmaceutical company; second-quarter operating loss was $3.1 million and net loss was $4.1 million.

Cumberland Pharmaceuticals Trading Down 6.1%

Shares of Cumberland Pharmaceuticals stock traded down $0.46 during mid-day trading on Thursday, hitting $7.09. The stock had a trading volume of 9,682 shares, compared to its average volume of 498,389. The firm has a 50-day moving average of $6.39 and a two-hundred day moving average of $4.78. The firm has a market cap of $106.22 million, a P/E ratio of -9.96 and a beta of 0.08. The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25. Cumberland Pharmaceuticals has a 12-month low of $1.85 and a 12-month high of $8.23.

Cumberland Pharmaceuticals Dividend Announcement

The company also recently declared a dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd were paid a $1.50 dividend.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth about $1,358,000. Dimensional Fund Advisors LP boosted its stake in Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after buying an additional 27,980 shares during the period. Bridgeway Capital Management LLC increased its position in shares of Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after acquiring an additional 4,200 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals in the 4th quarter valued at approximately $192,000. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CPIX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.